TyRx, Inc., Expands Market and Introduces Bioresorbable AIGISRx R Antibacterial Envelope
The Scope of a Successful Licensing Relationship Grows
TyRx, Inc., a New Jersey-based company, commercializes innovative, implantable combination drug-plus-device products focused on infection control, including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with Cardiac Implantable Electronic Devices (CIEDs).
The AIGISRx Antibacterial Envelope, a combination drug-device product, utilizes novel anti-bacterial coating technologies and patents jointly developed by Dr. Rabih Darouiche at Baylor College of Medicine and Dr. Issam Raad at The University of Texas MD Anderson Cancer Center. The novel coating technologies contain the antimicrobial agents, rifampin and minocycline, which have been shown to significantly reduce surgical site infection by pathogens responsible for the majority of CIED infections, including bacteria such as MRSA.
In June 2013, Baylor and TyRx Inc. agreed to an expanded field of use under their current license agreement. This field of use expansion will allow TyRx to sell its signature antibacterial products in new markets such as implantable infusion devices (i.e., drug pumps) and pulse generators (i.e. vagus nerve stimulators). Additionally, TyRx recently announced that it had received FDA clearance to market its fully resorbable AIGISRx R Antibacterial Envelope for use with pacemakers and implantable cardioverter defibrillators. The AIGISRx R is TyRx’s second-generation antibacterial mesh envelope, which provides device stabilization and infection reduction, but also has the added benefit of being a fully resorbable product.